SK Biopharmaceuticals announced on Dec. 23 that it has licensed out Cenobamate technology to Endo International, a specialty pharmaceutical company based in Dublin, Ireland.
Cenobamate is a medication used for the treatment of partial-onset seizures, a kind of epilepsy. It is sold under the brand names Xcopri (the U.S.) and Ontozry (EU). SK Biopharmaceuticals obtained approval on Cenobamate from the U.S. Food and Drug Administration (FDA) in November 2019 and has been selling it in the U.S. since May 2020 through SK Life Science, its U.S. subsidiary.
Through this partnership with Endo International, SK Biopharmaceuticals will be able to sell Cenobamate in Canada.
SK Biopharmaceuticals will receive US$20 million in down payment and 21 million Canadian dollars in technology fees (milestones) from Endo International. It will also receive royalties on sales.
The launch of Cenobamate will be handled by Paladin Labs, a Canadian subsidiary of Endo International.